Molecular Cancer Therapeutics

Scope

Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the Journal’s main focus is on small molecule and protein drugs, other molecular entities may be considered.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts

Online manuscript submission is welcomed at http://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at http://mct.aacrjournals.org.

Publication Charges

Beginning with manuscripts submitted January 1, 2016 or after, articles will be published with the understanding that the author(s) will pay both a publication fee plus a color figure handling fee. Please see the Instructions for Authors, which are available from the Journal’s home page at http://mct.aacrjournals.org.

Advertising Information

For information about advertising in AACR journals, contact Pharmaceutical Media Inc., 30 East 33rd St., 4th Floor, New York, NY 10016; 212-904-0360; Dsimone@pminy.com

Copyright and Permissions

Content printed in or disseminated by Molecular Cancer Therapeutics is protected by copyright. Authors who wish to publish material in Molecular Cancer Therapeutics must formally transfer copyright to the AACR. All authors must sign copyright transfer forms before the AACR can proceed with publication.

To read the complete AACR Copyright and Permissions Policy, visit http://aacrjournals.org/content/authors/copyright-permissions-and-access

Print ISSN: 1535-7163 • Online ISSN: 1538-8514

Scope

Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the Journal’s main focus is on small molecule and protein drugs, other molecular entities may be considered.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts

Online manuscript submission is welcomed at http://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at http://mct.aacrjournals.org.

Publication Charges

Beginning with manuscripts submitted January 1, 2016 or after, articles will be published with the understanding that the author(s) will pay both a publication fee plus a color figure handling fee. Please see the Instructions for Authors, which are available from the Journal’s home page at http://mct.aacrjournals.org.

Advertising Information

For information about advertising in AACR journals, contact Pharmaceutical Media Inc., 30 East 33rd St., 4th Floor, New York, NY 10016; 212-904-0360; Dsimone@pminy.com

Copyright and Permissions

Content printed in or disseminated by Molecular Cancer Therapeutics is protected by copyright. Authors who wish to publish material in Molecular Cancer Therapeutics must formally transfer copyright to the AACR. All authors must sign copyright transfer forms before the AACR can proceed with publication.

To read the complete AACR Copyright and Permissions Policy, visit http://aacrjournals.org/content/authors/copyright-permissions-and-access